A Future-Oriented Loan For Inura

 

“100 fürs Baselbiet” is an initiative organized by BLKB, the University of Applied Sciences Northwestern Switzerland FHNW, and the Baselland Economic Development Agency. This future-oriented program facilitates access to financial resources as well as advisory services for innovative SMEs and start-ups related to the Basel area.

 

The “100 fürs Baselbiet” purpose is based on strong collaborations between industry, science, and government. The goal is to help SMEs and start-ups to expand. Besides, this initiative intends to enhance the attractiveness and innovative capabilities, create jobs, and add economic value to the region. Interested companies have gone through a two-stage selection process. First, you submit your business idea with the associated financial plan. Afterward, if there is positive feedback, an independent advisory board assesses the companies’ applications pre-selected in so-called pitches. Subsequently, the Advisory Board decides which ideas and companies will receive support. 

 

The selected companies receive financing in the form of loans from BLKB. Obtaining this loan indicates the confidence that the Advisory Board has in the project and the team. The criteria are, among other things, the innovative strength and sustainability of the ideas presented and the quality of the entrepreneurial team. At HEMEX, we believe as well on Inura’s project and its team. Therefore, we are thrilled to see them acomplishing this achievement.

 

Inura Medical is developing an innovative urethral suppository for women with Overactive Bladder Syndrome (OAB). This highly prevalent and disabling health disorder has a significant impact on 20% of the female population’s quality of life. For instance, sleep deprivation, fatigue, nocturia, or memory lapses. Unfortunately, around 70-90% of the patients discontinue the available treatments because of their side effects. Inura Medical’s new, patented design suppository facilitates the effective penetration of drugs through the urethral mucosal lining. This new route of administration has greater therapeutic efficacy, and there are fewer side effects. Moreover, Inura Medical’s technology will reduce healthcare costs related to the treatment of OAB. Thanks to its partnership with HEMEX, Inura can complete an entire development program until Phase 3 in which the effects of the oral and urethral administration of the drug will be compared.

 

Hemex has a strong track record in women’s health and we immediately saw the potential of Inura’s urethral suppository platform. If you would like to know more about Inura, check their website HERE.